Stock DNA
Non Banking Financial Company (NBFC)
INR 342 Cr (Micro Cap)
NA (Loss Making)
20
0.15%
0.00
-1.70%
0.68
Total Returns (Price + Dividend) 
Latest dividend: 35 per share ex-dividend date: Jul-08-2025
Risk Adjusted Returns v/s 
Returns Beta
News
Why is Bombay Oxygen falling/rising?
As of 11-Nov, Bombay Oxygen Investments Ltd is experiencing a decline in its stock price, currently at Rs 23,277.00, which reflects a decrease of Rs 423.0 or 1.78%. The stock has been underperforming, having lost 3.29% over the last three days, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has shown significant underperformance over various periods, with a year-to-date decline of 21.23% compared to a 7.34% increase in the Sensex. Although there has been a rise in delivery volume by 36.36% against the 5-day average, the overall negative momentum and consecutive price falls indicate a challenging environment for the stock. Broader Market Context: In the short term, Bombay Oxygen's performance has been notably weaker than the benchmark, with a 1-week return of -1.98% compared to the Sensex's gain of 0.49%. This trend of underperformance is con...
Read MoreIs Bombay Oxygen overvalued or undervalued?
As of 3 November 2025, the valuation grade for Bombay Oxygen has moved from very expensive to risky. The company is currently assessed as overvalued. Key ratios indicate significant financial distress, with a PE ratio of -42.06, an EV to EBITDA of -32.75, and a Price to Book Value of just 0.07, highlighting the company's struggles in generating profits and managing its capital effectively. In comparison to its peers, Bombay Oxygen's valuation metrics are starkly unfavorable. For instance, Linde India, categorized as very expensive, has a PE ratio of 114.15, while Petronet LNG, rated very attractive, boasts a PE of 11.54. The stark contrast in these ratios underscores the challenges faced by Bombay Oxygen in the current market landscape. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -16.78%, significantly lagging behind the Sensex's gain of 7.47% ...
Read MoreHow has been the historical performance of Bombay Oxygen?
Answer: The historical performance of Bombay Oxygen shows a steady increase in net sales and profit over the years from 2009 to 2011. Breakdown: Bombay Oxygen's net sales rose from 32.51 Cr in March 2009 to 41.74 Cr in March 2011, indicating a consistent growth trend. The total operating income mirrored this increase, reaching 41.74 Cr in March 2011, up from 32.51 Cr in March 2009. The company's operating profit (PBDIT) also improved significantly, growing from 4.59 Cr in March 2009 to 8.84 Cr in March 2011. Profit before tax followed a similar upward trajectory, increasing from 0.90 Cr in March 2009 to 5.24 Cr in March 2011, while profit after tax rose from 0.59 Cr to 4.15 Cr in the same period. The earnings per share (EPS) saw a remarkable rise from 39.13 in March 2009 to 276.4 in March 2011. However, cash flow from operating activities showed a decline, moving from 3.74 Cr in March 2009 to -0.42 Cr in M...
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
01-Nov-2025 | Source : BSEIntimation of Newspaper Publication on 1st November 2025 w.r.t. Unaudited Financial Results for the quarter and half year ended 30th September 2025.
Unaudited Financial Results For The Quarter And Half-Year Ended 30Th September 2025
31-Oct-2025 | Source : BSEPlease find attached herewith Unaudited Financial Results for the Quarter and Half Year ended 30th September 2025
Appointment of Company Secretary and Compliance Officer
31-Oct-2025 | Source : BSEAppointment of Ms. Anshika Pal (A78049) as the Company Secretary and Compliance Officer of the Company with effect from 1st November 2025 as detailed in the enclosed attachment.
Corporate Actions 
No Upcoming Board Meetings
Bombay Oxygen Investments Ltd has declared 35% dividend, ex-date: 08 Jul 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
M Ramnarain Pvt. Ltd. (22.41%)
Shubh Pharma Pvt Ltd (3.75%)
14.62%
Quarterly Results Snapshot (Standalone) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is -119.73% vs 303.16% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is -121.54% vs 296.99% in Jun 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -56.24% vs 47.71% in Sep 2024
Growth in half year ended Sep 2025 is -58.03% vs 44.10% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'24
YoY Growth in nine months ended Dec 2024 is -40.82% vs 540.04% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -39.04% vs 589.70% in Dec 2023
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -71.47% vs 2,603.82% in Mar 2024
YoY Growth in year ended Mar 2025 is -69.60% vs 1,070.73% in Mar 2024






